This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AGN-192024, bimatoprost, Latisse
Description: BioMedTracker has separate drug profiles for the Lumigan and Latisse. Please also see Latisse.
The active ingredient of Lumigan, Bimatoprost, is a prostamide, a synthetic structural analog of prostaglandin that mimics the effects of naturally occurring prostamides. Lumigan is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
In May 2004, Allergan entered into an exclusive licensing agreement with Senju Pharmaceutical under which Senju became responsible for the development and commercialization ofLumigan in Japan. Senju incurs associated costs, makes clinical development and commercialization milestone payments and makes royalty basedpayments on product sales. Allergan agreed to work collaboratively with Senju on overall product strategy and management.
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.
In March 2015, Actavis announced that it has completed the acquisition of Allergan in a cash and equity transaction valued at approximately $70.5...See full deal structure in Biomedtracker
Partners: Senju Pharmaceutical Co., Ltd.
Pink Sheet Lumigan FDA Reviewers
Pink Sheet Lumigan Clinical Development
Pink Sheet Lumigan Clinical Protocols
Additional information available to subscribers only: